Research & Development


  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Q&A

    For Duchenne-focused Sarepta, gene therapy is the natural next step

    The company with three marketed RNA drugs for Duchenne muscular dystrophy is taking the logical leap into gene therapies with a candidate under review at the FDA.

    By Dec. 8, 2022
  • Beatrice McQueen WoW image
    Image attribution tooltip
    Permission granted by Beatrice McQueen
    Podcast

    Woman of the Week: Simcha Therapeutics’ Beatrice McQueen

    From sea sponges to cytokines, the chief operating officer’s career has come full circle as she pursues a new approach to treating cancer via the immune system.

    By Dec. 7, 2022
  • Professional headshot of Mahesh Karande
    Image attribution tooltip

    Permission granted by Mahesh Karande

    Profile

    Chasing a ‘holy grail’ cancer gene

    Omega Therapeutics’ president and CEO Mahesh Karande on its attempts to drug the elusive c-Myc gene.

    By Alexandra Pecci • Dec. 6, 2022
  • Addiction brain
    Image attribution tooltip
    Rafik via Getty Images

    AI company zeros in on compounds to treat addiction by rewiring the brain

    GATC Health is driving a novel approach it believes could work for several major neurological conditions.

    By Kelly Bilodeau • Dec. 5, 2022
  • lightbulb breaking
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    Healthcare tech’s biggest busts

    The metaverse, blockchain, DCTs and more — here are some of the most recent fails in healthcare tech.

    By Dec. 2, 2022
  • Overhead view of a person holding two white pills in their left hand and a glass of water in their right hand.
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    Non-toxic and addiction free: The promise of a new pain med

    Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

    By Dec. 1, 2022
  • pills
    Image attribution tooltip
    Stock via Getty Images

    10 of our most popular articles in 2022

    Methadone, rock ‘n’ roll, clinical trial overhauls — here’s a look at our most-read stories of the year.

    By Nov. 30, 2022
  • Alison O'Neill B&W head shot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Surface Oncology’s Dr. Alison O’Neill

    With more than two decades of experience in oncology R&D, Dr. Alison O’Neill is helping Surface unlock the potential of next-gen immunotherapies by targeting the tumor microenvironment.

    By Nov. 30, 2022
  • A team of four people wearing white lab coats stand looking at a computer in a medical science laboratory.
    Image attribution tooltip
    Stock via Getty Images

    One biotech’s approach to science-driven innovation

    Why some in the industry say fostering creativity in drug development is all about work structures.

    By Nov. 29, 2022
  • Skin
    Image attribution tooltip
    Ivan Balvan via Getty Images
    Q&A // Biotech Spotlight

    Evommune’s unique method of drug discovery is more than skin deep

    The biotech is using human skin squares from plastic surgery to find the best immunological molecules for solving conditions like dermatitis.

    By Nov. 29, 2022
  • Psychedelic
    Image attribution tooltip
    Danylana via Getty Images

    Avoiding a ‘bad trip’ in psychedelic clinical trials

    Psychedelic drug trials pose a number of challenges, but researchers can take these steps to boost patient safety.

    By Kelly Bilodeau • Nov. 28, 2022
  • Nicole Lambert WoW picture
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Myriad Genetics’ Nicole Lambert

    Empowered by her own cancer journey, Nicole Lambert is using her platform as chief operating officer of the genetic testing powerhouse to change the trajectory of care for millions of women.

    By Nov. 23, 2022
  • A view of a sign that reads, "Kendall square: central square, Harvard square, cinema" is framed by a pill outline.
    Image attribution tooltip

    Photo illustration: Shaun Lucas and Karissa Waddick/Industry Dive; Getty Images 

    The next era of Greater Boston’s biotech boom

    How Boston became the biotech capital of the U.S., and is now preparing for the next era of life sciences growth.  

    By , , Nov. 22, 2022
  • Professional headshot of Evelina Vågesjö
    Image attribution tooltip

    Permission granted by Evelina Vågesjö 

    Profile

    How bacteria-enabled technology for wounds could also help cancer patients

    Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.

    By Alexandra Pecci • Nov. 22, 2022
  • lab tubes
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    In cancers with very low survival rates, Sellas aims higher

    The company hopes its drugs can “take over where other available treatments fail” in multiple types of cancer.

    By Kelly Bilodeau • Nov. 21, 2022
  • Artificial intelligence in healthcare
    Image attribution tooltip
    ArtemisDiana via Getty Images

    Is AI just hype or a real revolution in pharma? It’s complicated

    Artificial intelligence can be a useful tool and will likely augment many processes in biopharma — but it's still early days, and hype is rampant.

    By Nov. 17, 2022
  • Francisco Barriga and Kaloyan Tsanov of the Sloan Kettering Institute
    Image attribution tooltip
    Permission granted by Memorial Sloan Kettering Cancer Center

    To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’

    A new CRISPR-based tool could help scientists understand and better treat cancer by revealing the complex genetic mutations that occur.

    By Nov. 16, 2022
  • Professional headshot of Sana Alajmovic.
    Image attribution tooltip

    Permission granted by Sana Alajmovic

    Profile

    A ‘bold vision’ to prevent diabetes

    Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

    By Alexandra Pecci • Nov. 15, 2022
  • COVID vaccine development
    Image attribution tooltip
    iStock via Getty Images

    4 ways to bring COVID’s ‘warp speed’ to the next era of drug development

    An IQVIA Institute for Human Data Science report outlines how companies can improve communication, recruitment, data and investing strategies to accelerate clinical trial timelines.

    By Kelly Bilodeau • Nov. 14, 2022
  • Glen de Vries blue origin
    Image attribution tooltip
    Permission granted by Medidata
    Q&A

    The legacy of Glen de Vries: Our last interview with the pioneering entrepreneur

    Recorded just weeks before his passing, our sit-down interview with the legendary medical sciences entrepreneur showcased his passion for pushing the industry toward its next frontier.

    By Nov. 11, 2022
  • Lene Oddershede
    Image attribution tooltip
    Permission granted by Lene Oddershede
    Q&A

    Novo Nordisk’s quantum bet on ‘world changing’ computing

    Behind the pharma giant’s plans to build the first quantum computer by 2034 to accelerate drug development.

    By Nov. 10, 2022
  • Professional headshot of Joe Landolina
    Image attribution tooltip

    Permission granted by Cresilon

    Profile

    This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

    29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.

    By Nov. 9, 2022
  • Tier Bryant, 82VS
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: 82VS’s Trier Bryant

    Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Not every leader makes it their mission to go where the fire ...

    By Nov. 9, 2022
  • Rami Elghandour headshot
    Image attribution tooltip
    Permission granted by Rami Elghandour
    Profile

    Chasing that ‘Time magazine cover potential’

    Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

    By Alexandra Pecci • Nov. 8, 2022
  • IV infusion
    Image attribution tooltip
    Amornrat Phuchom via Getty Images

    While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help

    Facing an unprecedented manufacturing bottleneck, a new coalition is aiming to create the next generation of CAR-T therapies.

    By Nov. 8, 2022